Drug Diabetes

Jardiance

Payments companies reported to CMS as associated with Jardiance. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$35Massociated payments (2023-2025)

113,654clinicians with associated payments

6companies reporting

By year

2023 $12M

2024 $15M

2025 $8.8M

Payments reported as associated with Jardiance, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $7.0M

Endocrinology, Diabetes & Metabolism $6.1M

Nephrology (Internal Medicine) $3.9M

Internal Medicine $3.1M

Family Medicine $2.8M

Advanced Heart Failure and Transplant Cardiology $2.7M

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Jardiance

These are the largest totals companies reported as associated with Jardiance. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Javed Butler	Jackson, MS	Advanced Heart Failure and Transplant Cardiology	$364,113.61
Christian Mende	La Jolla, CA		$215,108.10
Lance Sloan	Lufkin, TX	Endocrinology, Diabetes & Metabolism	$206,370.70
John Osborne	Grapevine, TX	Cardiovascular Disease	$200,385.10
Michael Aaronson	Lincoln, NE	Nephrology (Internal Medicine)	$186,639.58
Ku Juey Chang	Lake Forest, CA	Endocrinology, Diabetes & Metabolism	$175,399.11
Leigh Perreault	Boulder, CO	Endocrinology, Diabetes & Metabolism	$161,094.18
Robert Busch	Albany, NY	Endocrinology, Diabetes & Metabolism	$154,226.50
Sasikanth Adigopula	Indianapolis, IN	Advanced Heart Failure and Transplant Cardiology	$151,516.31
Patrick Simpson	Pinehurst, NC	Interventional Cardiology	$151,081.62

Prescribed Jardiance?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.